UPDATE OF THE TRANSACTION ANNOUNCED ON NOVEMBER 25, 2025, FOR THE ACQUISITION OF THE MINORITY INTEREST IN THE SUBSIDIARY GROUPE TECHNOLOGIQUE KDA INC.
Theralase Technologies closes $1.33-million financing
Algernon increases placement, closes third tranche
Bausch Health Announces Final Results and Expiration of Exchange Offers
LSL Pharma completes $10M closing of debenture offering
LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZED $12M OFFERING
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
Profound closes $36-million offering
Quantum Biopharma completes dosing in Lucid-MS studies
Algernon Announces Increase to Private Placement Financing to $750,000 and Close of Third Tranche
NEW CHIEF EXECUTIVE OFFICER INVESTORS UPDATE
LSL PHARMA GROUP CLOSES $10M OF UPSIZED $12M BROKERED OFFERING AND ENTERS INTO DEFINITIVE AGREEMENT FOR THE ACQUISITION OF JUNO OTC
Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
Entheon Announces Letter of Intent with Nutravisor Inc.